Are current dosage forms really as easy and convenient for patients as pharma manufacturers say they are?

Nanoparticles help to deliver a three-in-one attack on metastatic melanoma cells

From anti-cancer viruses to H3 blocking narcolepsy drugs – we present a year in European drug approvals

We live in exciting times for the biopharma industry.

A clinical trial of an FAAH inhibitor in France goes terribly wrong, but whether the compound or manufacturing are to blame remains to be seen

Are you worried about implementing new manufacturing technology in your plant? Never fear, the FDA’s Emerging Technology Team may be able to lend a helping hand

Lipoprotein-nanoplatelets leave researchers hungry to explore drug delivery potential

Oncology medication prices can vary significantly between countries – but by how much and why?

How do we move on from a sombre start to 2016?

Many drug candidates are as poorly soluble as “brick dust”, making oral delivery a significant challenge.